Cantor Fitzgerald Expects Higher Earnings for GH Research

GH Research PLC (NASDAQ:GHRS - Free Report) - Research analysts at Cantor Fitzgerald upped their FY2025 earnings estimates for GH Research in a report issued on Tuesday, March 4th. Cantor Fitzgerald analyst C. Duncan now expects that the company will post earnings of ($0.79) per share for the year, up from their previous forecast of ($0.80). Cantor Fitzgerald has a "Overweight" rating and a $14.00 price objective on the stock. The consensus estimate for GH Research's current full-year earnings is ($0.80) per share.

GH Research (NASDAQ:GHRS - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.06.

Other analysts also recently issued reports about the company. HC Wainwright reiterated a "buy" rating and set a $40.00 target price on shares of GH Research in a research report on Monday, January 27th. Royal Bank of Canada started coverage on shares of GH Research in a report on Friday. They set an "outperform" rating and a $31.00 price objective for the company. Canaccord Genuity Group dropped their target price on shares of GH Research from $31.00 to $28.00 and set a "buy" rating on the stock in a research note on Monday, November 18th. Finally, Stifel Nicolaus lifted their price target on shares of GH Research from $18.00 to $32.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $30.67.

Remove Ads

GH Research Stock Up 6.7 %

GHRS traded up $0.70 during trading hours on Thursday, reaching $11.20. 421,447 shares of the company's stock traded hands, compared to its average volume of 162,909. The firm has a 50-day moving average price of $10.80 and a 200 day moving average price of $9.17. The firm has a market capitalization of $582.71 million, a PE ratio of -14.18 and a beta of 0.94. GH Research has a 52-week low of $6.00 and a 52-week high of $20.50.

Hedge Funds Weigh In On GH Research

Large investors have recently bought and sold shares of the business. RA Capital Management L.P. increased its holdings in shares of GH Research by 1.3% in the 3rd quarter. RA Capital Management L.P. now owns 6,686,689 shares of the company's stock valued at $44,734,000 after acquiring an additional 85,000 shares during the period. Lynx1 Capital Management LP boosted its position in GH Research by 15.8% during the fourth quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company's stock valued at $34,013,000 after purchasing an additional 663,100 shares in the last quarter. Diadema Partners LP bought a new stake in GH Research during the fourth quarter valued at about $711,000. Woodline Partners LP grew its stake in GH Research by 112.0% in the fourth quarter. Woodline Partners LP now owns 78,949 shares of the company's stock valued at $553,000 after purchasing an additional 41,711 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in GH Research by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 72,513 shares of the company's stock worth $508,000 after purchasing an additional 3,092 shares in the last quarter. Institutional investors own 56.90% of the company's stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).